Prof Alistair Nichol (Dublin & Melbourne) discusses why the REMAP-CAP adaptive platform trial has chosen to investigate ivermectin, given the controversy surrounding this agent.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"Critical Care Reviews Podcast","authorlink":""},"src":"https:\/\/traffic.libsyn.com\/secure\/ccrpodcast\/Ivermectin_Pre_Auphonic.mp3?dest-id=316836","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202309\/f5f2b5-1d86-ae0f-2fae30_800.png"},"title":"Ivermectin","link":"javascript:;","id":"item-5536340"}]
